ROCTAVIAN
Total Payments
$1.1M
Transactions
450
Doctors
91
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 441 | 89 |
| 2023 | $6,938 | 9 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $873,245 | 171 | 79.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $173,888 | 83 | 15.9% |
| Travel and Lodging | $28,692 | 63 | 2.6% |
| Food and Beverage | $9,046 | 120 | 0.8% |
| Consulting Fee | $6,957 | 11 | 0.6% |
| Royalty or License | $3,100 | 1 | 0.3% |
| Education | $997.00 | 1 | 0.1% |
Payments by Type
Research
$873,245
171 transactions
General
$222,680
279 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $428,378 | 0 |
| BMN 270-401 | BioMarin Pharmaceutical Inc. | $282,361 | 0 |
| Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3) | BioMarin Pharmaceutical Inc. | $63,012 | 0 |
| Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | BioMarin Pharmaceutical Inc. | $60,546 | 0 |
| BMN 293-101 | BioMarin Pharmaceutical Inc. | $27,827 | 0 |
| BMN 270-703 | BioMarin Pharmaceutical Inc. | $11,122 | 0 |
Top Doctors Receiving Payments for ROCTAVIAN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $876,345 | 172 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $34,692 | 36 |
| , M.D | Pediatrics | Peoria, IL | $15,927 | 6 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $14,982 | 9 |
| , MD | Orthopaedic Surgery | Broomall, PA | $14,400 | 9 |
| Maissaa Janbain | Specialist | New Orleans, LA | $13,747 | 10 |
| , MD | Hematology | Saint Louis, MO | $11,807 | 10 |
| , MD | Pediatrics | Ann Arbor, MI | $10,818 | 9 |
| , MD | Pediatrics | Bronx, NY | $10,183 | 10 |
| , MD | Hematology & Oncology | Louisville, KY | $9,788 | 10 |
| , M.D | Pediatric Hematology-Oncology | Orange, CA | $9,741 | 10 |
| , M.D | Pediatrics | Iowa City, IA | $9,574 | 10 |
| , APNP | Hematology & Oncology | Green Bay, WI | $8,905 | 21 |
| , MD | Pediatrics | Miami, FL | $7,693 | 6 |
| , MD | Pediatrics | Orange, CA | $7,406 | 10 |
| , MD | Internal Medicine | Minneapolis, MN | $5,594 | 6 |
| , MD | Pediatrics | Cleveland, OH | $5,471 | 4 |
| , MD PHD | Internal Medicine | Washington, DC | $4,374 | 5 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $3,800 | 5 |
| , MB BCHIR | Internal Medicine | Charleston, SC | $3,478 | 4 |
| , MD, PHD | Pediatric Hematology-Oncology | New Haven, CT | $3,049 | 8 |
| , MD | Pediatric Hematology-Oncology | Slidell, LA | $2,962 | 2 |
| , MD | Hematology & Oncology | Milwaukee, WI | $2,671 | 3 |
| , M.D., PHD | Hematology & Oncology | Sacramento, CA | $2,620 | 1 |
| , MD | Hematology & Oncology | Seattle, WA | $2,100 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 91
- Transactions 450
About ROCTAVIAN
ROCTAVIAN is a drug associated with $1.1M in payments to 91 healthcare providers, recorded across 450 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2023 to 2024. In 2024, $1.1M was paid across 441 transactions to 89 doctors.
The most common payment nature for ROCTAVIAN is "Unspecified" ($873,245, 79.7% of total).
ROCTAVIAN is associated with 6 research studies, including "Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients" ($428,378).